PhaseBio Pharmaceuticals Inc (27)

Browse by Contract Category

Contracts

Acknowledgement of Grant of a Sublicense in Accordance with the License Agreement between Medimmune Limited and PhaseBio Pharmaceuticals, Inc. and Related Options (Filed With SEC on August 12, 2021)
Supply Agreement, dated as (Filed With SEC on May 13, 2021)
Underwriting Agreement, dated March 17, 2021 (Filed With SEC on March 19, 2021)
Non-Employee Director Compensation Policy, as amended (Filed With SEC on March 15, 2021)
Co-Development Agreement, dated January 9, 2020, by and between PhaseBio Pharmaceuticals, Inc. and SFJ Pharmaceuticals X, Ltd (Filed With SEC on March 30, 2020)
License Agreement, dated as of June 16, 2021, by and between PhaseBio Pharmaceuticals, Inc. and Alfasigma, S.p.A (Filed With SEC on August 12, 2021)
Consent and First Amendment to Loan and Security Agreement, dated as of March 19, 2020, by and among PhaseBio Pharmaceuticals, Inc. and Silicon Valley Bank and WestRiver... (Filed With SEC on March 30, 2020)
Asset Purchase Agreement, dated January 13, 2020, by and between PhaseBio Pharmaceuticals, Inc., Viamet Pharmaceuticals Holdings, LLC and Selenity Therapeutics (Bermuda), Ltd (Filed With SEC on March 30, 2020)
Form of Program Transfer Agreement by and between PhaseBio Pharmaceuticals Inc. and SFJ Pharmaceuticals X. Ltd (Filed With SEC on March 30, 2020)
Intellectual Property Security Agreement, dated as of March 19, 2020, by and among PhaseBio Pharmaceuticals, Inc. and Silicon Valley Bank and WestRiver Innovation Lending Fund... (Filed With SEC on March 30, 2020)
Subordination Agreement, dated as of March 19, 2020, by and among Silicon Valley Bank, WestRiver Innovation Lending Fund VIII, L.P. and SFJ Pharmaceuticals X, Ltd (Filed With SEC on March 30, 2020)
Amendment to License Agreement, dated January 9, 2020, by and between PhaseBio Pharmaceuticals, Inc. and MedImmune Limited (Filed With SEC on March 30, 2020)
Description of PhaseBio Pharmaceuticals, Inc. Common Stock (Filed With SEC on March 30, 2020)
Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to SFJ Pharmaceuticals X, Ltd. on January 9, 2020 (Filed With SEC on March 30, 2020)
Non-Employee Director Compensation Policy, as amended (Filed With SEC on February 13, 2020)
Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to WestRiver Innovation Lending Fund VIII, L.P. on October 2, 2019 (Filed With SEC on November 14, 2019)
Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to Silicon Valley Bank on October 2, 2019 (Filed With SEC on November 14, 2019)
Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to Silicon Valley Bank on July 26, 2019 (Filed With SEC on August 14, 2019)
Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to WestRiver Innovation Lending Fund VIII, L.P. on July 26, 2019 (Filed With SEC on August 14, 2019)
License Agreement, dated April 1, 2019, by and between PhaseBio Pharmaceuticals, Inc. and Wacker Biotech GmbH (Filed With SEC on April 9, 2019)
Form of Underwriting Agreement (Filed With SEC on April 9, 2019)
Eighth Amendment to License Agreement, dated as of March 5, 2019, by and between PhaseBio Pharmaceuticals, Inc. and Duke University (Filed With SEC on April 9, 2019)
Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to WestRiver Innovation Lending Fund VIII, L.P. on March 25, 2019 (Filed With SEC on March 26, 2019)
Loan and Security Agreement, dated as of March 25, 2019, by and among PhaseBio Pharmaceuticals, Inc. and Silicon Valley Bank and WestRiver Innovation Lending Fund VIII, L.P (Filed With SEC on March 26, 2019)
Master Services Agreement, dated as of November 14, 2018, by and between PhaseBio Pharmaceuticals, Inc. and BioVectra Inc (Filed With SEC on March 26, 2019)
Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to Silicon Valley Bank on March 25, 2019 (Filed With SEC on March 26, 2019)
Non-Employee Director Compensation Policy, as amended (Filed With SEC on March 4, 2019)